David Charles Link - 07 Dec 2022 Form 4 Insider Report for SAB Biotherapeutics, Inc. (SABS)

Role
Director
Signature
/s/ David Charles Link
Issuer symbol
SABS
Transactions as of
07 Dec 2022
Transactions value $
$49,999
Form type
4
Filing time
09 Dec 2022, 08:01:53 UTC
Previous filing
15 Feb 2022
Next filing
17 Jul 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SABS Common Stock Award $50K +41.5K +262.28% $1.21 57.3K 07 Dec 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SABS Warrant (Common Stock) Award +41.5K 41.5K 07 Dec 2022 Common Stock 41.5K $1.08 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 6, 2022, the Registrant entered into a securities purchase agreement with Mr. David Link in connection with a private placement conducted by the Registrant, pursuant to which Mr. Link purchased (i) an aggregate of 41,493 shares (the "Shares") of the Registrant's common stock, par value $0.0001 per share and (ii) warrants to purchase up to an aggregate of 41,493 shares of common stock at an exercise price of $1.08, at a combined purchase price of $1.205 per share and accompanying warrant. The warrants are exercisable six months from the date of issuance and expire five years from the date of issuance.

Remarks:

The Reporting Person states that the filing of this Form 4 shall not be deemed an admission that the Reporting Person is the beneficial owner of the reported securities other than those directly owned by the Reporting Person for the purpose of Section 16, or for any other purpose.